GlassScriptPhysician profile
Jordan Bacon
NPI 1982228847
$6,949.75
in general payments reported to CMS, 2019-2025
24 companies · $59.52 in 2025
The $59.52 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,179 · 2022: $2,106 · 2023: $1,809 · 2024: $1,796 · 2025: $59.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,664.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,948.05 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,891.06 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $461.36 | 2021-2024 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $405.01 | 2021-2024 | Ocaliva |
| Janssen Biotech, INC. | $398.67 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Daiichi Sankyo INC. | $349.79 | 2021-2024 | Injectafer |
| Gilead Sciences, INC. | $300.03 | 2021-2024 | |
| Ardelyx, INC. | $190.93 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $186.28 | 2021-2024 | Sucraid |
| Genzyme Corporation | $131.35 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $116.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $96.20 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $93.60 | 2021-2023 | |
| Lilly USA, LLC | $74.48 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $55.66 | 2021-2023 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.67 | 2024 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.98 | 2023-2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $35.51 | 2022-2024 | Dificid |
| Aimmune Therapeutics, INC. | $31.65 | 2024 | |
| Braintree Laboratories, INC. | $29.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $20.93 | 2023 | Imjudo |
| Celgene Corporation | $20.29 | 2024 | Zeposia |
| Inogen, INC. | $16.30 | 2024 | |
| Celltrion USA INC. | $14.43 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.